Replay available

Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call

Lucid Diagnostics Inc. (NASDAQ: LUCD) Q2 2026 earnings conference call, held 2026-08-13. Replay captured from the company's public earnings webcast.

Thu, August 13, 2026 at 8:30 AMendedReplay
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Matt Riley

Vice President, Investor Relations

Dr. Lishan Aklog

Chairman and Chief Executive Officer

Dennis McGrath

Chief Financial Officer

Alex Cacason

Analyst (on for Kyle Mixon)

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Lucid Diagnostics Second Quarter 2026 Business Update Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, August 13, 2026. I would now like to turn the conference over to Matt Riley, Lucid Diagnostics Vice President of Investor Relations. Please go ahead. Thank you, Operator, and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of Lucid Diagnostics, along with Dennis McGrath, Chief Financial Officer. The press release announcing our business update and financial results is available on Lushan's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update, press release, and conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings to the SEC. For a list and a description of these and other important risks and uncertainties that may affect future operations, see Part 1, Item 1A, entitled Risk Factors in Lishan's most recent Annual Report on Forms 10-K, filed with the SEC, and any subsequent updates filed in Quarter Reports on Forms 10-Q and subsequent Forms 8-K. Except as required by law, LUCID disclaims any intentions or obligation...

More from Lucid Diagnostics Inc.